ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team (Q33976896)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team |
scientific article |
Statements
1 reference
ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team (English)
1 reference
M Fischl
1 reference
M F Para
1 reference
P Meehan
1 reference
J Holden-Wiltse
1 reference
G Morse
1 reference
R Shafer
1 reference
L M Demeter
1 reference
K Wood
1 reference
T Nevin
1 reference
N Virani-Ketter
1 reference
W W Freimuth
1 reference
1 June 1999
1 reference
1 reference
43
1 reference
1373-1378
1 reference
1 reference
Identifiers
1 reference
1 reference